|
www.aurobindo.com |
|
|
Hyderabad, 6th October, 2005 |
|
|
|
AUROBINDO GETS EDQM APPROVAL FOR
FLUCLOXACILLIN SODIUM |
|
|
|
Aurobindo Pharma Limited (Reuters
Code: ARBN.BO) is pleased to announce
that it has received the Certificate of
Suitability of monographs of the European
Pharmacopoeia by the European Directorate for
the Quality of Medicines (EDQM) for its Active
Pharmaceutical Ingredients (API)
Flucloxacillin Sodium. |
|
Flucloxacillin
Sodium belongs to the group of medicines known
as antibiotics. Flucloxacillin is used primarily
for the treatment of infections due to
staphylococci resistant to benzyl penicillin.
Aurobindo Pharma Limited has started receiving
approvals to penetrate in the European market.
Aurobindo has filed several DMFs/CoS/Formulation
dossiers with various applicable authorities in
Europe for its product range. With the
endorsement from European Directorate for the
Quality of Medicines (EDQM), Aurobindo Pharma
will be able to sell the above products in whole
of Europe. |
|
About Aurobindo Pharma Limited: |
|
Aurobindo Pharma
Limited (www.aurobindo.com),
headquartered at Hyderabad, India, manufactures
generic pharmaceuticals and active
pharmaceutical ingredients. The company has
received approvals for several facilities from
leading regulatory agencies like US FDA, UK MHRA,
WHO, Health Canada, MCC South Africa. The
company’s robust product portfolio is spread
over 6 major therapeutic/product areas
encompassing (Antibiotics, Anti-Retrovirals,
CVS, CNS, Gastroenterologicals, and Anti-Allergics)
around 65 APIs in the non-antibiotics and 55
APIs in the antibiotic segment. The company is
marketing these products globally, in over 100
countries. |
|
|
|
|
|
PRESS
ROOM
